Clinical risk–benefit assessment of dopamine agonists
暂无分享，去创建一个
K. Chaudhuri | J. C. Möller | P. Odin | K. Eggert | M. Unger | W. Oertel | Per Odin | Marcus M. Unger | Jens Carsten Möller | W. H. Oertel | Karla Eggert | K. Chaudhuri
暂无分享，去创建一个
K. Chaudhuri | J. C. Möller | P. Odin | K. Eggert | M. Unger | W. Oertel | Per Odin | Marcus M. Unger | Jens Carsten Möller | W. H. Oertel | Karla Eggert | K. Chaudhuri